Navigation Links
VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
Date:4/4/2013

SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors.  The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.

Haig Keledjian , CEO of VG Life Sciences, said, "We are happy to report we attained the safety endpoints we anticipated for our second cohort of patients.  Similar to the positive results we announced previously for our first patient cohort, no significant toxicities were observed at a higher dose of HCQ in combination with sorafenib.  We have begun enrolling patients into the next dosing cohort in this dose-escalation study and look forward to reporting those results in a timely fashion.  We anticipate patient recruitment to accelerate since opening up the enrollment criteria to include patients with breast, colon, lung, liver, pancreatic, and ovarian cancer, and look forward to an ultimate study completion date, from a safety standpoint, of third quarter 2013."

Dr. Tyler Curiel , gynecological oncologist at the Cancer Therapy & Research Center in San Antonio, TX, and principal investigator for the trial said, "Having successfully finished enrollment in cohort two, we have begun treating patients in the third cohort. The safety of our patients is pa
'/>"/>

SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
2. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
4. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
5. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
6. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
7. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
8. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
9. PointCross Life Sciences SENDBox and SEND-as-a-Service Prepare Pharma Companies to Comply with the FDAs Upcoming e-Data Submission Mandate
10. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
11. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets has ... Therapeutics Market & Pipeline Insight 2014" report to ... to prevent and eradicate the prevalence of cancer have ... confined to low specificity, safety and large number of ... a better solution. It has been discovered that peptides ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... Where do you start when trying to minimize the ... independent nonprofit that researches the best approaches to improving patient ... its 5th annual list of Top 10 Health Technology ... download with registration, the list features the top 10 ...
... Dec. 7, 2010 Millennium Research Group (MRG), the ... release their latest data on the US clot management ... for Clot Management Devices 2011 report provides important ... and the complex competitive dynamics of medical device manufacturers ...
Cached Medicine Technology:ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 2ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 3Millennium Research Group to Release Their Latest US Clot Management Data 2
(Date:8/29/2014)... As reported by CNN.com in the article ... process of admitting that you need help for a prescription ... and highlights the fact that if you simply try to ... overwhelmed by all of the information that is available online. ... through, it is still possible to get help. The statistics ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to new ... But Not Peer Pressure, Key to Prescription Drug Misuse Among ... primary focus for 18-29 year olds when it comes to ... the for this age group the real problem which influences ... drug associations and recreational use of them to have fun ...
(Date:8/29/2014)... article entitled How Genes, Gender and Environment Influence Substance ... gender and the environment that an individual is in affect ... Indiana University are taking another look at the fact that ... this factor to what is known about the influences of ... ties can help to reduce a man’s risk for abusing ...
(Date:8/29/2014)... 29, 2014 Formed in 2014, KAJ Brothers ... beyond their years. Their sophisticated Pop/R&B sound, with beautiful ... is fortunate enough to experience every day. , ... uplifted and feeling loved with the primary purpose of elevating ... this, the group unanimously replied - “To make chivalry cool ...
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... which will give patients the convenience of visiting ... with Healthpointe doctors through telemedicine. , Healthpointe doctors are ... calls (or audio). If necessary, the doctor can even ... assessed the patient’s condition, he or she can prescribe ...
Breaking Medicine News(10 mins):Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 2Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 2Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2
... WASHINGTON, June 4 Walgreen Co. of,Deerfield, Ill., ... claims that from,2001 to 2005, it improperly switched ... Fluoxetine and Eldepryl in order to,increase its reimbursement ... which operates over 5,000 retail pharmacies throughout the,U.S., ...
... TORONTO, June 4 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. ... appeal the,recent decision made by American Stock Exchange (the ... appeal determination process, the,Company,s stock will continue to trade ... to trade on the Toronto Stock Exchange (the "TSX"),under ...
... patients who lose nerve signals , , WEDNESDAY, June 4 ... improved after receiving human neural stem cell transplants, a ... substance that plays a critical role in the transmission ... missing or damaged, electrical signals aren,t properly transmitted. These ...
... (48%) of high,school teens say they have had sex--an increase ... by the Centers for Disease Control,and Prevention. During the same ... used a condom the last time they had sex decreased ... Youth Risk Behavior Surveillance,System. The survey is administered every two ...
... A failed drug launch can cost,a pharmaceutical ... end,up costing a company more. Leading pharmaceutical companies ... sales with a re-launch, according to a,study by ... As best-in-class pharma companies have demonstrated, combining ...
... Two members of Easter Seals national,corporate partner family -- ... across the Chicagoland area to bring value to consumers, ... consumers visiting any Chicagoland CENTURY,21(R) office or open house ... or transferred prescription is brought to CVS/pharmacy for use ...
Cached Medicine News:Health News:Walgreens to Pay $35 Million to U.S., 46 States & Puerto Rico to Settle Medicaid Prescription Drug Fraud Allegations 2Health News:PreMD Appeals American Stock Exchange Delisting Notification 2Health News:Human Stem Cell Transplant Helps Brain-Impaired Mice 2Health News:Teen Sexual Activity Increases, Contraceptive Use Decreases 2Health News:Redefining a Product's Identity Key to a Successful Re-Launch 2Health News:CVS/pharmacy and CENTURY 21(R) Team Up With Easter Seals Around Chicagoland 2
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: